PlasmaGen Biosciences, a Bengaluru-based biopharmaceutical company, has raised ₹150 crore in a funding round led by ViNS Bioproducts, taking its valuation past ₹1,500 crore. The round attracted participation from pharmaceutical entrepreneurs, family offices, high-net-worth individuals and existing investors, reflecting rising investor interest in India’s plasma-derived therapeutics sector.
Funding bolsters growth and manufacturing scale-up
The fresh capital lifts PlasmaGen’s cumulative fundraising above ₹600 crore and arrives as the company scales manufacturing capacity and prepares for overseas market entry. Management says the funds will support international regulatory filings, distribution partnerships and an expansion of its product portfolio to address unmet clinical needs.
Strategic investments and operational priorities
PlasmaGen plans to deploy proceeds across leadership hires, operational efficiencies and manufacturing infrastructure to ensure sustainable, large-scale production. The company’s investor base includes Eight Roads Ventures, F-Prime Capital and FIL Capital Investments alongside the new lead investor, signalling continued institutional confidence.
Building domestic capability in plasma-derived medicines
Founded in 2010, PlasmaGen develops and manufactures plasma-derived therapies such as immunoglobulins, albumin, clotting factors and anti‑D immunoglobulin—products used to treat immune deficiencies, bleeding disorders, liver ailments and certain neurological conditions.
India has historically relied on imports for many of these complex biologics, resulting in supply volatility and higher costs. By expanding local fractionation and downstream manufacturing, PlasmaGen aims to improve access to essential therapies and reduce dependency on overseas suppliers, aligning with national goals for healthcare self-reliance.
Kolar facility strengthens domestic supply chains
A major milestone for the company was the commercial commissioning of its plasma fractionation plant in Kolar, Karnataka, in late 2023. One of the relatively few private-sector fractionation units in India, the Kolar facility enables scalable plasma processing and contributes to steadier supplies of life‑saving medicines to hospitals and specialised care centres.
Operationalising domestic fractionation capacity also helps shorten supply chains, lower import exposure and support price stability for hospitals and payers—factors important for broader adoption of specialised biological therapies in Indian healthcare settings.
Outlook: poised for domestic consolidation and global outreach
With demand for specialised biologics growing globally and within India, PlasmaGen’s latest funding round positions the company to consolidate its domestic manufacturing base while pursuing regulated market entry abroad. The firm’s stated focus on regulatory approvals and distribution partnerships is aimed at converting manufacturing scale into greater patient access and commercial traction in select international markets.
As PlasmaGen expands its product range and production footprint, it is emerging as a notable participant in India’s evolving plasma therapeutics ecosystem—one that industry observers say will be critical to improving availability and affordability of complex biologic medicines nationwide.
